- Home
- MRM vs NKGN Comparison
MRM vs NKGN Comparison
Compare MRM & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- NKGN
- Stock Information
- Founded
- MRM 2000
- NKGN 2017
- Country
- MRM Japan
- NKGN United States
- Employees
- MRM N/A
- NKGN N/A
- Industry
- MRM Other Consumer Services
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRM Consumer Discretionary
- NKGN Health Care
- Exchange
- MRM Nasdaq
- NKGN Nasdaq
- Market Cap
- MRM 12.2M
- NKGN 14.1M
- IPO Year
- MRM 2020
- NKGN N/A
- Fundamental
- Price
- MRM $1.04
- NKGN $0.50
- Analyst Decision
- MRM
- NKGN
- Analyst Count
- MRM 0
- NKGN 0
- Target Price
- MRM N/A
- NKGN N/A
- AVG Volume (30 Days)
- MRM 485.8K
- NKGN 711.5K
- Earning Date
- MRM 01-01-0001
- NKGN 12-24-2024
- Dividend Yield
- MRM N/A
- NKGN N/A
- EPS Growth
- MRM N/A
- NKGN N/A
- EPS
- MRM N/A
- NKGN N/A
- Revenue
- MRM $44,462,062.00
- NKGN N/A
- Revenue This Year
- MRM N/A
- NKGN N/A
- Revenue Next Year
- MRM N/A
- NKGN N/A
- P/E Ratio
- MRM N/A
- NKGN N/A
- Revenue Growth
- MRM 2.80
- NKGN N/A
- 52 Week Low
- MRM $0.95
- NKGN $0.20
- 52 Week High
- MRM $8.39
- NKGN $4.06
- Technical
- Relative Strength Index (RSI)
- MRM 24.39
- NKGN 59.45
- Support Level
- MRM $0.95
- NKGN $0.45
- Resistance Level
- MRM $3.70
- NKGN $0.55
- Average True Range (ATR)
- MRM 0.35
- NKGN 0.07
- MACD
- MRM -0.19
- NKGN 0.00
- Stochastic Oscillator
- MRM 3.28
- NKGN 47.48
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.